{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T23:13:01Z","timestamp":1787008381503,"version":"build-2736575974"},"reference-count":14,"publisher":"Oxford University Press (OUP)","issue":"Supplement_5","license":[{"start":{"date-parts":[[2025,3,22]],"date-time":"2025-03-22T00:00:00Z","timestamp":1742601600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,8,19]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>The prevalence of Candida infections increases each year in the US. The most common Candida species are\u00a0Candida albicans,\u00a0Candida glabrata,\u00a0Candida parapsilosis,\u00a0Candida tropicalis, and\u00a0Candida krusei.\u00a0Because of concerns about emerging resistance and impact on clinical outcomes, selection of appropriate empiric antifungal therapy is crucial. At our institution, an antifungalgram was created to help monitor antifungal susceptibility patterns.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A retrospective chart review was conducted at UnityPoint Health\u2013Des Moines for the time period from January 2013 to July 2023. Patients were included if they had a sterile site culture positive for C. albicans,\u00a0C. glabrata,\u00a0C. parapsilosis, C. krusei, or C. tropicalis. Species were excluded if the sample size was fewer than 10 isolates or if susceptibility data were not available. The objective of this study was to evaluate the quantity and type of sterile site Candida species isolates and antifungal susceptibility to create an antifungalgram.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>This study reviewed 251 sterile site Candida isolates, of which 242 were included. Of the 242 sterile site isolates, 218 (90.1%) were from adult patients and 24 (9.9%) were from neonatal\/pediatric patients. C. albicans was the most common organism with 132 (54.5%) isolates, followed by C. glabrata (74 isolates, 30.6%), C. parapsilosis (25 isolates, 10.3%), and C. tropicalis (11 isolates, 4.5%). The susceptibility rates for each Candida species were summarized.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The creation of a local antifungalgram helps to detect resistance patterns within healthcare systems and may guide empiric antifungal therapy selection.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ajhp\/zxaf070","type":"journal-article","created":{"date-parts":[[2025,3,20]],"date-time":"2025-03-20T00:28:29Z","timestamp":1742430509000},"page":"S2951-S2954","source":"Crossref","is-referenced-by-count":1,"title":["Antifungalgram: A unique tool to track fungal resistance"],"prefix":"10.1093","volume":"82","author":[{"given":"Zoey","family":"Sjogren","sequence":"first","affiliation":[{"name":"Pharmacy, UnityPoint Health , Des Moines, IA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda","family":"Bushman","sequence":"additional","affiliation":[{"name":"Pharmacy, UnityPoint Health , Des Moines, IA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessi","family":"Holter","sequence":"additional","affiliation":[{"name":"Pharmacy, UnityPoint Health , Des Moines, IA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sudhir","family":"Kumar","sequence":"additional","affiliation":[{"name":"Infectious Diseases, UnityPoint Health , Des Moines, IA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,3,22]]},"reference":[{"issue":"10","key":"2025081819562961900_CIT0001","doi-asserted-by":"publisher","first-page":"1455","DOI":"10.1086\/497138","article-title":"The changing face of fungal infections in health care settings","volume":"41","author":"Fridkin","year":"2005","journal-title":"Clin Infect Dis"},{"key":"2025081819562961900_CIT0002","author":"Centers for Disease Control and Prevention"},{"issue":"4","key":"2025081819562961900_CIT0003","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1093\/cid\/civ933","article-title":"Clinical practice guideline for the management of candidiasis: 2016 update by the Infectious Diseases Society of America","volume":"62","author":"Pappas","year":"2016","journal-title":"Clin Infect Dis"},{"issue":"3","key":"2025081819562961900_CIT0004","doi-asserted-by":"publisher","first-page":"e1012055","DOI":"10.1371\/journal.ppat.1012055","article-title":"Renaming Candida glabrata\u2014a case of taxonomic purity over clinical and public health pragmatism","volume":"20","author":"Denning","year":"2024","journal-title":"PLoS Pathog"},{"issue":"2","key":"2025081819562961900_CIT0005","doi-asserted-by":"publisher","first-page":"dlab060","DOI":"10.1093\/jacamr\/dlab060","article-title":"The antibiogram: key considerations for its development and utilization","volume":"3","author":"Truong","year":"2021","journal-title":"JAC Antimicrob Resist"},{"issue":"9","key":"2025081819562961900_CIT0006","doi-asserted-by":"publisher","first-page":"1306","DOI":"10.1592\/phco.27.9.1306","article-title":"The utility of hospital antibiograms as tools for guiding empiric therapy and tracking resistance. Insights from the Society of Infectious Diseases Pharmacists","volume":"27","author":"Pakyz","year":"2007","journal-title":"Pharmacotherapy"},{"key":"2025081819562961900_CIT0007","volume-title":"Analysis and Presentation of Cumulative Antimicrobial Susceptibility Test Data","author":"Clinical and Laboratory Standards Institute","year":"2022","edition":"5th ed"},{"issue":"suppl 1","key":"2025081819562961900_CIT0008","doi-asserted-by":"publisher","first-page":"i33","DOI":"10.1093\/jac\/dkx447","article-title":"Overview of antifungal dosing in invasive candidiasis","volume":"73","author":"Pea","year":"2018","journal-title":"J Antimicrob Chemother"},{"key":"2025081819562961900_CIT0009","volume-title":"Performance Standards for Antifungal Susceptibility Testing of Yeasts","author":"Clinical and Laboratory Standards Institute","year":"2020","edition":"2nd ed"},{"key":"2025081819562961900_CIT0010","volume-title":"Performance Standards for Antifungal Susceptibility Testing of Yeasts","author":"Clinical and Laboratory Standards Institute","year":"2017","edition":"1st ed"},{"key":"2025081819562961900_CIT0011","author":"European Committee on Antimicrobial Susceptibility Testing","year":"2020"},{"key":"2025081819562961900_CIT0012","author":"Nebraska Medicine"},{"issue":"8","key":"2025081819562961900_CIT0013","doi-asserted-by":"publisher","first-page":"1877","DOI":"10.1093\/jac\/dkae175","article-title":"Initial micafungin treatment does not improve outcomes compared to fluconazole treatment in immunocompromised and critically ill patients with candidaemia","volume":"79","author":"Theodore","year":"2024","journal-title":"J Antimicrob Chemother"},{"issue":"5","key":"2025081819562961900_CIT0014","doi-asserted-by":"publisher","first-page":"1262","DOI":"10.1128\/JCM.02416-16","article-title":"Establishment and use of epidemiological cutoff values for molds and yeasts by use of the Clinical and Laboratory Standards Institute M57 standard","volume":"55","author":"Lockhart","year":"2017","journal-title":"J Clin Microbiol"}],"container-title":["American Journal of Health-System Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ajhp\/advance-article-pdf\/doi\/10.1093\/ajhp\/zxaf070\/62523411\/zxaf070.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ajhp\/article-pdf\/82\/Supplement_5\/S2951\/62523411\/zxaf070.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ajhp\/article-pdf\/82\/Supplement_5\/S2951\/62523411\/zxaf070.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,18]],"date-time":"2025-08-18T23:56:31Z","timestamp":1755561391000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ajhp\/article\/82\/Supplement_5\/S2951\/8090375"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,22]]},"references-count":14,"journal-issue":{"issue":"Supplement_5","published-online":{"date-parts":[[2025,3,22]]},"published-print":{"date-parts":[[2025,8,19]]}},"URL":"https:\/\/doi.org\/10.1093\/ajhp\/zxaf070","relation":{},"ISSN":["1079-2082","1535-2900"],"issn-type":[{"value":"1079-2082","type":"print"},{"value":"1535-2900","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,9,1]]},"published":{"date-parts":[[2025,3,22]]}}}